{
    "organizations": [],
    "uuid": "2e7eb029bf80259f7d8975612b8d19e9ce87ea8c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-pharming-announces-fda-acceptance/brief-pharming-announces-fda-acceptance-for-review-of-supplemental-biologics-license-application-idUSASM000I74",
    "ord_in_thread": 0,
    "title": "BRIEF-Pharming Announces FDA Acceptance For Review Of Supplemental Biologics License Application",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 17 (Reuters) - PHARMING GROUP NV:\n* PHARMING ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS\n* ‍FDA INDICATED SBLA IS SUFFICIENTLY COMPLETE TO PERMIT SUBSTANTIVE REVIEW\n* ‍FDA SET AN ACTION DATE OF SEPTEMBER 21, 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-17T14:27:00.000+02:00",
    "crawled": "2018-01-18T16:10:55.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "pharming",
        "group",
        "nv",
        "pharming",
        "announces",
        "fda",
        "acceptance",
        "review",
        "supplemental",
        "biologics",
        "license",
        "application",
        "prophylaxis",
        "hereditary",
        "angioedema",
        "attack",
        "indicated",
        "sbla",
        "sufficiently",
        "complete",
        "permit",
        "substantive",
        "review",
        "set",
        "action",
        "date",
        "september",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}